BCR-ABL
The BCR-ABL fusion results in constitutive ABL tyrosine kinase activity contributing to unregulated cell division. The BCR-ABL fusion is found in 95% of chronic myelogenous leukemia (CML), 25–30% adult acute lymphoblastic leukemia (ALL), and 2–10% child ALL. Researchers have identified the utility of measuring BCR-ABL transcripts to aid in the assessment of minimal residual disease (MRD) and the response to treatment. An international consortium has developed “International Standards” allowing the comparison of BCR-ABL levels measured by different quantitative PCR assays.
CytoGenes offers primer mixes, standards, and controls allowing laboratories to detect the three most common BCR-ABL fusions by quantitative PCR (b2a2, b3a2, and e1a2). A set of standards normalized to the International Scale allows results to be reported on the International Scale.
The graphs below demonstrate the high degree of correlation between the NIBSC and CytoGenes International Scale Standards for both the b2a2 and b3a2 BCR-ABL fusion products.
References
|
Additional Product Information
|
|
BCR-ABL Primer Mixes Product Data Sheet BCR-ABL Controls Product Data Sheet BCR-ABL Standards Product Data Sheet |